CAJ | 학술논문

目的：研究乌司他丁对重症烧伤患者体内炎症因子水平的影响,为临床重症烧伤患者的治疗提供依据。方法对2010年1月~2013年6月我院入院治疗的94例重度烧伤患者进行了研究,分为两组,对照组给予常规治疗,包括补液、抗休克、早期切削痂手术以及营养支持等,治疗组患者在上述治疗方案基础上,加用乌司他丁,连续治疗7d,比较治疗前后两组患者血常规、体内炎症因素水平变化以及APACHE II评分(acute physiology and chronic health evaluation,急性生理与慢性健康评分)。结果与治疗前比较,两组患者白细胞(white blood cells,WBC)、中性粒细胞数量明显降低,血小板(blood platelet,)数量明显升高,且治疗组患者改善更明显,差异有统计学意义(P<0.05)。两组患者全身炎症反应综合征(systemic inflammatory response syndrome,SIRS)诊断时APACHE II评分基本相当,72h后有明显差异,治疗组明显低于对照组,差异有统计学意义(P<0.05)；治疗组患者肿瘤坏死因子α(tumor necrosis factor alpha,TNF-α)和白介素-6(interleukin-6,IL-6)的水平明显低于对照组,白介素-2(interleukin-2,IL-2)和白介素-10(interleukin-10,IL-10)的水平明显高于对照组,差异有统计学意义(P<0.05)。结论乌司他丁能够明显的改善患者体内的炎症状态,对于改善患者的症状,防止并发症的发生具有重要的意义。
목적：연구오사타정대중증소상환자체내염증인자수평적영향,위림상중증소상환자적치료제공의거。방법대2010년1월~2013년6월아원입원치료적94례중도소상환자진행료연구,분위량조,대조조급여상규치료,포괄보액、항휴극、조기절삭가수술이급영양지지등,치료조환자재상술치료방안기출상,가용오사타정,련속치료7d,비교치료전후량조환자혈상규、체내염증인소수평변화이급APACHE II평분(acute physiology and chronic health evaluation,급성생리여만성건강평분)。결과여치료전비교,량조환자백세포(white blood cells,WBC)、중성립세포수량명현강저,혈소판(blood platelet,)수량명현승고,차치료조환자개선경명현,차이유통계학의의(P<0.05)。량조환자전신염증반응종합정(systemic inflammatory response syndrome,SIRS)진단시APACHE II평분기본상당,72h후유명현차이,치료조명현저우대조조,차이유통계학의의(P<0.05)；치료조환자종류배사인자α(tumor necrosis factor alpha,TNF-α)화백개소-6(interleukin-6,IL-6)적수평명현저우대조조,백개소-2(interleukin-2,IL-2)화백개소-10(interleukin-10,IL-10)적수평명현고우대조조,차이유통계학의의(P<0.05)。결론오사타정능구명현적개선환자체내적염증상태,대우개선환자적증상,방지병발증적발생구유중요적의의。
Objective To research the influence of ulinastatin on body inflammatory factor levels in patients with severe burns, and provide the basis treatment of patients with severe burns. Methods A total of 94 patients from Jan 2010 to June 2013 were studied in this test. The control group was treated with basic therapy including fluid infusion, antishock, cutting scab surgery and early nutrition support while the treatment group was received ulinastatin on the basic of control. Routine blood, body inflammatory factors level change and APACHE II score were compared between the two groups, Results The number of WBC and neutrophil in treatment group was higher than control 1group (P <0.05), while the PLT was lower than control group (P<0.05). The APACHE II score was in the same level between the two groups before treatment, while the score of treatment group was obvious lower than control control group after 72hr (P<0.05). The TNF-α and IL-6 in treatment group was lower than control wihle the IL-2 and IL-10 was higher than control(P<0.05). Conclusion Ulinastatin played an important role in improving the patient's body state of inflammation, the patient's symptom and preventing complications.